Contineum Therapeutics (CTNM) EBT (2023 - 2026)

Contineum Therapeutics' EBT history runs 4 years deep, the most recent figure standing at -$56.8 million for Q2 2026.

• In Q2 2026, EBT fell 149.44% year-over-year to -$56.8 million; the TTM figure through Jun 2026 stood at -$147.0 million (down 101.76% YoY), while the FY2025 annual figure was -$107.8 million, down 155.13% from the prior year.
• EBT for Q2 2026 stood at -$56.8 million, down from -$41.5 million in the prior quarter.
• The five-year high for EBT was $42.3 million in Q2 2023, with the low at -$56.8 million in Q2 2026.
• The 4-year median for EBT is -$12.4 million (2024), against an average of -$15.3 million.
• Peak annual rise in EBT reached 9.56% in 2025, while the deepest fall reached 219.79% in 2025.
• Contineum Therapeutics' EBT stood at -$7.9 million in 2023, then plunged by 83.67% to -$14.6 million in 2024, then retreated by 9.56% to -$16.0 million in 2025, then tumbled by 255.81% to -$56.8 million in 2026.
• Business Quant data shows CTNM's EBT at -$56.8 million in Q2 2026, -$41.5 million in Q1 2026, and -$16.0 million in Q4 2025.